Navigation Links
AutoImmune Inc. Reports 2008 First Quarter Financial Results
Date:5/9/2008

ements because they involve our expectations, beliefs, projections, anticipations or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. These factors include, but are not limited to the uncertainties of clinical trial results, the Company's dependence on third parties for licensing revenue, and the risks of technological change and competition. These factors are more fully discussed, as are other factors, in the Company's most recent Annual Report on Form 10-KSB filed with the Securities and Exchange Commission in the section entitled "Risk Factors."

AUTOIMMUNE INC.

STATEMENT OF OPERATIONS

(Unaudited)

Three months ended March 31,

2007 2008

Revenue $97,000 $67,000

Costs and expenses:

Cost of goods sold 9,000 12,000

Research and development 30,000 42,000

General and administrative 185,000 205,000

Total costs and expenses 224,000 259,000

Interest income 110,000 84,000

Minority interest in joint venture - 1,000

Other income 25,000 -

135,000 85,000

Net income (loss) $8,000 ($107,000)

Net income (loss) per share - basic $0.
'/>"/>

SOURCE AutoImmune Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. M.D. Anderson-led team reports possible key to autoimmune disease
2. Occupational exposures may be linked to death from autoimmune disease
3. AutoImmune Inc. Reports 2007 Third Quarter Financial Results
4. New protein discovery helps researchers understand autoimmune diseases
5. Video: New Autoimmunity Public Service Campaign Alerts Men About Their Autoimmune Disease Risk
6. Mergent, Inc. Announces Changes to the HealthShares(TM) Composite, Enabling Technologies, Autoimmune-Inflammation, Cancer, Cardiology and Neuroscience Indexes
7. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
8. Haemacure Reports Third Quarter 2007 Results
9. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
10. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
11. MDS Reports Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/13/2008)... HARBIN, China, May 13 /Xinhua-PRNewswire-FirstCa...oard: CSKI), a manufacturer, marketer and,distribu...oducts in China,today announced that it will cond... May 15, 2008 to discuss its first quarter 2008 fi...man, CEO and Director of China Sky One,Medical, In...
(Date:5/13/2008)...ildbearing had no such benefit if baby was bottle-...13 (HealthDay News) -- Women who breast feed for m...arthritis (RA) by half, according to a new Swedish...g children but not breast-feeding offered women no...contraceptives also failed to reduce the risk of R...
(Date:5/13/2008)...NEW YORK (May 13, 2008) -- Promising results from ...ell Medical Center physician-scientists show that ... the progression of Batten disease, or Late Infant..., genetic, degenerative neurological disorder that... to 12. , The clinical trial found that the pro...
(Date:5/13/2008)... SALT LAKE CITY, May 13 /PRNewswire/ -- Paramed S...ent of their marine-grade Mobility Offers,Versatil...chair to oil and,gas platform operators in the Gul...platforms will enable the safe and timely evacuati...atform., Paramed developed the dual-track MOV in ...
Breaking Medicine News(10 mins):Health News:China Sky One Medical, Inc. Announces Conference Call to Discuss First Quarter 2008 Results 2Health News:Breast-feeding Might Shield Women From Rheumatoid Arthritis 2Health News:NYP/Weill Cornell gene therapy clinical trial yields promising results for Batten disease 2
...ltinational team of researchers based in the UK ha...s biological barriers, opening up the potential fo...rchers from the School of Pharmacy, University of ...otubes by adding a range of different functional g...
...U.S. Food and Drug Administration (FDA) today clea... device that can help save the arms and legs of so...ndividuals in other trauma settings and emergency ... Limb Salvage Shunt (TLSS), made by Vascutek Ltd. ...
...a's drug major Ranbaxy Laboratories has received t...pproval to manufacture// and market its formulatio...in adults. Ranbaxy Pharmaceuticals Inc. (RPI), a ...oratories Limited (RLL), announced Friday that FDA...
...he recent years, scientists discovered a family of...xtend life in organisms// as diverse as yeast, wor...t The Wistar Institute points to another strategy ...ir anti-aging powers. They may also be able to con...
Other Medicine News:Health News:Carbon Nanoneedles For Drug Delivery 2Health News:Carbon Nanoneedles For Drug Delivery 3Health News:Carbon Nanoneedles For Drug Delivery 4Health News:FDA Clears Critical Limb-Saving Vascular Device 2Health News:Anti-Aging Powers of Enzyme Sirtuins 2
(Date:5/12/2008)...Patients in Cohort 3 Demonstrated Improvement in T...rapeutic Potential of HspE7, SAN DIEGO, May 12 /P...Corporation (TSX: NVN) today announced positive im...ing Phase 1 clinical trial of its lead product,can...helial neoplasia, or,CIN, a precursor to cervical ...
(Date:5/9/2008)...A, Fla., May 9 /PRNewswire-USNewswire/ -- Osteoart...ondition that affects almost 50,million people in ...f,cartilage in bone joints. The novel investigatio... oral analgesic, provided significant relief,for p... treated with,placebo, and with fewer gastrointest...
(Date:5/9/2008)...TTLE, May 9 /PRNewswire-USNewswire/ -- The risk of...n prostatic hyperplasia (BPH), can be,reduced by c...ntaining a,normal weight and eating a healthy diet...cer Prevention Program at Fred Hutchinson Cancer R...ies that suggest men need not,feel helpless agains...
(Date:5/9/2008)...th International Phase III Study Shows Positive Re...ata -, NUTLEY, N.J., May 9 /- Roche ...ar Phase III study showing that ACTEMRA(TM),(tocil...tructural damage to,joints in patients with rheuma...veness of an RA treatment. The study also demonstr...
Breaking Medicine Technology:Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 2Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 3Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 4Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 5Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 6Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 2Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 3Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 4Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 5Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Men's Health Week Is June 9-15) 2Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Men's Health Week Is June 9-15) 3Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Men's Health Week Is June 9-15) 4New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 2New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 3New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 4New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 5Memory in artificial atoms 4445 1Memory in artificial atoms 4445 2Faster Test Detects Fake Tamiflu Drugs 16192 1Faster Test Detects Fake Tamiflu Drugs 16192 2Chehalis Tribes Announce Benefit to Help Returning Combat Veterans 16187 1Chehalis Tribes Announce Benefit to Help Returning Combat Veterans 16187 2Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph 16183 1Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph 16183 2Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph 16183 3
... Vaginal Supplement Studied in Largest-Ever IVF Tr...PRNewswire/ -- Results of,four studies evaluating ...ogesterone vaginal insert in development for lutea...t for implantation and,the early stages of pregnan...re presented at the 55th Annual Meeting of the,Pac...
... N.J., April 18, 2007 /PRNewswire-FirstCall/ --,ON...rug candidate,may have potential as a chemopreven...ma researcher Michele Carbone M.D., Ph.D.,at this...AACR),Annual Meeting. , In a series of poster pres...ldwide problem of asbestos exposure and its link t...
Other Medicine Technology:Ferring Reports on ENDOMETRIN Presentations at Pacific Coast,Reproductive Society Annual Meeting 2Ferring Reports on ENDOMETRIN Presentations at Pacific Coast,Reproductive Society Annual Meeting 3Ferring Reports on ENDOMETRIN Presentations at Pacific Coast,Reproductive Society Annual Meeting 4Ferring Reports on ENDOMETRIN Presentations at Pacific Coast,Reproductive Society Annual Meeting 5Onconase has Potential as Chemopreventive Agent in Mesothelioma,Reports World-Renowned Mesothelioma Researcher at AACR Annual,Meeting 2Onconase has Potential as Chemopreventive Agent in Mesothelioma,Reports World-Renowned Mesothelioma Researcher at AACR Annual,Meeting 3Onconase has Potential as Chemopreventive Agent in Mesothelioma,Reports World-Renowned Mesothelioma Researcher at AACR Annual,Meeting 4
VG2 PLIF Allograft is comprised of two cortical planks of bone surrounding a cancellous center. The cortical planks provide strength for anterior column support. The cancellous bone provides a lattic
Williams Micro Discectomy Instruments are designed to be used in the microsurgical treatment of herniated disks.
Meyerding Laminectomy Retractors, self-retaining.
Karlin Crank Frame Spinal Retractor Set is designed for posterior lumbar and thoracic spine surgery. Arm design allows the blades be pre-positioned in the wound prior to attachment.
Medicine Products: